Apogee Therapeutics, Inc. (APGE) — Financial statements
Income statement, balance sheet, and cash flow for Apogee Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue & Gross Profit | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 1 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -1 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | |||||
| R&D Expenses | 215↑27.9% | 168↑145.3% | 68↑146.3% | 28 | |
| General & Administrative Expenses | 71↑44.6% | 49↑99.4% | 25↑735.7% | 3 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 71↑44.6% | 49↑99.4% | 25↑735.7% | 3 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 284↑31.0% | 217↑133.2% | 93↑202.7% | 31 | |
| Total Costs & Expenses | 286↑31.7% | 217↑133.2% | 93↑202.7% | 31 | |
| Operating Results | |||||
| Operating Income | -286↓31.7% | -217↓133.2% | -93↓202.7% | -31 | |
| Depreciation & Amortization | 1↑650.3% | 0.19↓97.9% | 9 | 0.00 | |
| EBITDA | -284↓31.1% | -217↓189.0% | -75↓88.4% | -40 | |
| EBIT | -286↓31.7% | -217↓158.2% | -84↓111.1% | -40 | |
| Interest & Other Income | |||||
| Net Interest Income | 30↓13.6% | 35↑285.3% | 9↑199.6% | -9 | |
| Interest Income | 30↓13.6% | 35↑285.3% | 9↑9702.2% | 0.09 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 9 | |
| Non-Operating Income | 0.00 | 0.00↑100.0% | -9↓199.6% | 9 | |
| Other Income / Expenses | 30↓13.6% | 35↑285.3% | 9↑199.6% | -9 | |
| Income Before Tax | -256↓40.3% | -182↓116.9% | -84↓111.1% | -40 | |
| Income Tax Expense | 0.28↑1444.4% | 0.02 | 0.00 | 0.00 | |
| Net Income & EPS | |||||
| Net Income from Continuing Operations | -256↓40.5% | -182↓116.9% | -84↓111.1% | -40 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -256↓40.5% | -182↓116.9% | -84↓111.1% | -40 | |
| Bottom-Line Net Income | -256↓40.5% | -182↓116.9% | -84↓111.1% | -40 | |
| EPS (Basic) | -4.22↓27.9% | -3.30↓98.8% | -1.66↓110.1% | -0.79 | |
| EPS (Diluted) | -4.22↓27.9% | -3.30↓98.8% | -1.66↓110.1% | -0.79 | |
| Weighted Average Shares | 61↑10.0% | 55↑9.0% | 51↓0.0% | 51 | |
| Weighted Average Diluted Shares | 61↑10.0% | 55↑9.0% | 51↓0.0% | 51 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.